Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BDX Stock Forecast 2025-2026
$189.50
Current Price
$54.35B
Market Cap
Buy 5
Hold 9
Sell 0
Wall St Analyst Ratings
Distance to BDX Price Targets
+42.5%
To High Target of $270.00
+3.4%
To Median Target of $195.96
-3.4%
To Low Target of $183.00
BDX Price Momentum
-0.5%
1 Week Change
+6.6%
1 Month Change
-15.0%
1 Year Change
-16.5%
Year-to-Date Change
-24.8%
From 52W High of $251.99
+16.8%
From 52W Low of $162.29
📊 TOP ANALYST CALLS
Did BDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Becton Dickinson is one of their latest high-conviction picks.
Latest BDX Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, BDX has a neutral consensus with a median price target of $195.96 (ranging from $183.00 to $270.00). The overall analyst rating is Buy (7.3/10). Currently trading at $189.50, the median forecast implies a 3.4% upside. This outlook is supported by 5 Buy, 9 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jayson Bedford at Raymond James, projecting a 42.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BDX Analyst Ratings
5
Buy
9
Hold
0
Sell
BDX Price Target Range
Low
$183.00
Average
$195.96
High
$270.00
Current: $189.50
Latest BDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 2, 2025 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $210.00 |
| Nov 7, 2025 | RBC Capital | Shagun Singh | Sector Perform | Maintains | $202.00 |
| Nov 7, 2025 | Piper Sandler | Jason Bednar | Neutral | Maintains | $190.00 |
| Oct 16, 2025 | RBC Capital | Shagun Singh | Sector Perform | Reiterates | $211.00 |
| Sep 25, 2025 | RBC Capital | Shagun Singh | Sector Perform | Initiates | $211.00 |
| Aug 11, 2025 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $197.00 |
| Aug 8, 2025 | Wells Fargo | Lawrence Biegelsen | Equal-Weight | Maintains | $184.00 |
| Aug 8, 2025 | Piper Sandler | Jason Bednar | Neutral | Maintains | $200.00 |
| Jun 3, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $241.00 |
| May 22, 2025 | Citigroup | Joanna Wiensch | Neutral | Downgrade | $185.00 |
| May 6, 2025 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $196.00 |
| May 2, 2025 | Stifel | Rick Wise | Buy | Maintains | $224.00 |
| May 2, 2025 | Piper Sandler | Jason Bednar | Neutral | Downgrade | $185.00 |
| May 1, 2025 | Citigroup | Buy | Maintains | $N/A | |
| May 1, 2025 | William Blair | Brian Weinstein | Market Perform | Downgrade | $N/A |
| Apr 23, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $260.00 |
| Apr 7, 2025 | Barclays | Travis Steed | Overweight | Maintains | $261.00 |
| Feb 14, 2025 | Barclays | Travis Steed | Overweight | Maintains | $279.00 |
| Jan 28, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $280.00 |
| Jan 22, 2025 | Barclays | Overweight | Maintains | $N/A |
Becton, Dickinson and Company (BDX) Competitors
The following stocks are similar to Becton Dickinson based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Becton, Dickinson and Company (BDX) Financial Data
Becton, Dickinson and Company has a market capitalization of $54.35B with a P/E ratio of 33.3x. The company generates $21.84B in trailing twelve-month revenue with a 7.7% profit margin.
Revenue growth is +8.3% quarter-over-quarter, while maintaining an operating margin of +17.9% and return on equity of +6.5%.
Valuation Metrics
Market Cap
$54.35B
Enterprise Value
$74.73B
P/E Ratio
33.3x
PEG Ratio
12.3x
Price/Sales
2.5x
Growth & Margins
Revenue Growth (YoY)
+8.3%
Gross Margin
+47.5%
Operating Margin
+17.9%
Net Margin
+7.7%
EPS Growth
+23.3%
Financial Health
Cash/Price Ratio
+1.2%
Current Ratio
1.1x
Debt/Equity
78.9x
ROE
+6.5%
ROA
+4.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Becton, Dickinson and Company (BDX) Business Model
About Becton, Dickinson and Company
What They Do
Develops and manufactures medical devices and systems.
Business Model
BD generates revenue through the sale of medical devices, instrument systems, and reagents across three segments: BD Medical, BD Life Sciences, and BD Interventional. The company serves various sectors including pharmaceuticals and clinical laboratories, ensuring a steady demand for its products and solutions.
Additional Information
BD is headquartered in Franklin Lakes, New Jersey and operates globally, emphasizing innovation, quality, and addressing healthcare challenges. Its products enhance patient safety and improve healthcare delivery, making it a key player in the healthcare industry.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
70,000
CEO
Mr. Thomas E. Polen Jr.
Country
United States
IPO Year
1983
Website
www.bd.comBecton, Dickinson and Company (BDX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing
BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.
Dec 05, 2025
By Zacks Equity Research
Analyst Blog
Hologic's BCI Test Shows Growing Impact in Endocrine Therapy Decisions
HOLX's BCI test gains traction as new SABCS studies are set to highlight its growing role in guiding extended endocrine therapy decisions.
Dec 04, 2025
By Moumi Mondal
Analyst Blog
Latest News
Quick Summary
BD and ChemoGLO announced a strategic collaboration to enhance hazardous drug contamination testing in healthcare, aiming to improve safety for healthcare workers.
Why It Matters
BD's partnership with ChemoGLO enhances its product offerings in safety and contamination testing, potentially boosting market share and driving revenue growth in the healthcare sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
BDX partners with ChemoGLO to enhance hazardous drug testing, focusing on improving safety in healthcare settings.
Why It Matters
BDX's partnership with ChemoGLO signals a commitment to improving safety standards, potentially increasing market share and driving revenue growth in the healthcare sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes
6 days ago
Quick Summary
BD has launched new three- and four-laser FACSDiscover™ A8 Cell Analyzers, enhancing accessibility to advanced cell analysis for various labs in academia and pharma sectors.
Why It Matters
The launch of new BD cell analyzers enhances market accessibility for advanced imaging tech, potentially boosting sales and expanding market share in the growing biotech and pharma sectors.
Source: PRNewsWire
Market Sentiment:
Neutral
Best Dividend Aristocrats For December 2025
10 days ago
Quick Summary
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has lagged behind SPY year-to-date but showed improvement in November. Dividend growth for 2025 averages 5.46%, with some stocks posting double-digit gains.
Why It Matters
The reversal in November and double-digit gains of key Dividend Aristocrats signal a potential recovery for NOBL, impacting income-focused investors and indicating sector performance trends.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Zacks Premium offers Style Scores to help investors identify strong stocks across value, growth, and momentum categories.
Why It Matters
Zacks Style Scores can enhance stock selection across investment strategies, potentially leading to better returns and informed decision-making for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
BD Surgiphor™ Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety
15 days ago
Quick Summary
BD (Becton, Dickinson and Company) has launched the BD Surgiphor™ Surgical Wound Irrigation System in Europe, expanding its product offerings in the medical technology sector.
Why It Matters
The launch of the BD Surgiphor™ Surgical Wound Irrigation System in Europe could drive revenue growth for BD, enhancing market position and potentially increasing stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BDX Stock
What is Becton, Dickinson and Company's (BDX) stock forecast for 2026?
Based on our analysis of 26 Wall Street analysts, Becton, Dickinson and Company (BDX) has a median price target of $195.96. The highest price target is $270.00 and the lowest is $183.00.
Is BDX stock a good investment in 2026?
According to current analyst ratings, BDX has 5 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $189.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BDX stock?
Wall Street analysts predict BDX stock could reach $195.96 in the next 12 months. This represents a 3.4% increase from the current price of $189.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Becton, Dickinson and Company's business model?
BD generates revenue through the sale of medical devices, instrument systems, and reagents across three segments: BD Medical, BD Life Sciences, and BD Interventional. The company serves various sectors including pharmaceuticals and clinical laboratories, ensuring a steady demand for its products and solutions.
What is the highest forecasted price for BDX Becton, Dickinson and Company?
The highest price target for BDX is $270.00 from Jayson Bedford at Raymond James, which represents a 42.5% increase from the current price of $189.50.
What is the lowest forecasted price for BDX Becton, Dickinson and Company?
The lowest price target for BDX is $183.00 from at , which represents a -3.4% decrease from the current price of $189.50.
What is the overall BDX consensus from analysts for Becton, Dickinson and Company?
The overall analyst consensus for BDX is neutral. Out of 26 Wall Street analysts, 5 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $195.96.
How accurate are BDX stock price projections?
Stock price projections, including those for Becton, Dickinson and Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 9, 2025 2:12 AM UTC